发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Compulsory licensing of patents. 专利的强制许可。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2022-0039
Narayanasamy Kumutha, Narayanasamy Amutha, Govindasamy S Venkatesh
{"title":"Compulsory licensing of patents.","authors":"Narayanasamy Kumutha,&nbsp;Narayanasamy Amutha,&nbsp;Govindasamy S Venkatesh","doi":"10.4155/ppa-2022-0039","DOIUrl":"https://doi.org/10.4155/ppa-2022-0039","url":null,"abstract":"<p><p>Compulsory licensing (CL) is a mechanism made by the government to provide balance between the monopoly right holders and the third person with public interest by ensuring the ease availability of the patented products at reasonable rate. This paper discusses the background criteria for getting CL in India as per the Indian Patent Act, 1970 starting from the concepts outlined in the Trade-Related Aspects of Intellectual Property Rights agreement. We reviewed the case studies for the accepted and rejected CL in India. We also discuss important CL cases that were permitted internationally, including the present COVID pandemic CL. Finally, we provide our analytical perspectives regarding the pros and cons of CL.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"225-231"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9153336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Papers from the First International Conference on Innovation and Intellectual Property Rights. 首届创新与知识产权国际会议论文。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2023-0004
Michael Bell, Runjhun Tandon
{"title":"Papers from the First International Conference on Innovation and Intellectual Property Rights.","authors":"Michael Bell,&nbsp;Runjhun Tandon","doi":"10.4155/ppa-2023-0004","DOIUrl":"https://doi.org/10.4155/ppa-2023-0004","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"163-164"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9551674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Therapeutic potential of Pogostemon cablin herb: a comprehensive review. 广藿香的治疗潜力综述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2022-0021
Archana Thakur
{"title":"Therapeutic potential of <i>Pogostemon cablin</i> herb: a comprehensive review.","authors":"Archana Thakur","doi":"10.4155/ppa-2022-0021","DOIUrl":"https://doi.org/10.4155/ppa-2022-0021","url":null,"abstract":"<p><p><i>Pogostemon cablin</i> (<i>Pogostemon patchouli</i> or Patchouli) is known for its essential oil and is a popular medicinal herb in Indian Ayurveda and traditional Chinese medicine. This review covers patent articles on the <i>P. cablin</i> plant's therapeutic effects. The patent literature was collected using a thorough, comprehensive search on databases like Thomson Innovation, Espacenet, Patentscope, The Lens and Patent digital libraries of different Jurisdictions, including IPO, USPTO, CNIPA, inPASS, KIPO, JPO, etc. Despite the vast number of review articles on non-patent literature, none of the articles reviewed the patent literature. This current <i>P. cablin</i> literature analysis study will facilitate bridging the gap between further exploring the potential of this plant through novel investigations.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"213-224"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9158148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19. 探讨因COVID-19豁免《与贸易有关的知识产权协定》后投资者索赔的风险。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2022-0034
Shrikant Kulkarni, Varinder Kaur
{"title":"Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.","authors":"Shrikant Kulkarni,&nbsp;Varinder Kaur","doi":"10.4155/ppa-2022-0034","DOIUrl":"https://doi.org/10.4155/ppa-2022-0034","url":null,"abstract":"<p><p>This research plans to explore the risks of the investment claims involved in the ongoing technology transfers to COVID-19 vaccine manufacturers based on the recently approved 'Agreement on Trade-Related Aspects of Intellectual Property Rights' (TRIPS) waiver. These investment claims are based on the various intellectual property rights protected under international investment laws. The recently approved TRIPS waiver only deals with the patent rights involved in producing the COVID-19 vaccine but does not deal with the other related intellectual property rights such as trade secrets. This work sounds the alarm of investment dispute for the mass-production of vaccines based on the TRIPS waiver. The research suggests a plan by which the Indian government can address the global issue of COVID-19 technology transfer in India.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"165-174"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9353447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent developments in silver nanoparticles utilized for cancer treatment and diagnosis: a patent review. 用于癌症治疗和诊断的银纳米颗粒的最新发展:专利审查。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2022-0010
Shripad M Patil, Runjhun Tandon, Nitin Tandon
{"title":"Recent developments in silver nanoparticles utilized for cancer treatment and diagnosis: a patent review.","authors":"Shripad M Patil,&nbsp;Runjhun Tandon,&nbsp;Nitin Tandon","doi":"10.4155/ppa-2022-0010","DOIUrl":"https://doi.org/10.4155/ppa-2022-0010","url":null,"abstract":"<p><p>Nanotheranostics is a young but rapidly expanding science that incorporates elements of therapy and diagnostics in a unique and miniscule area of research. The potential to combine diagnostic and therapeutic abilities inside a complete unit opens up interesting possibilities for innovative biomedical research. Silver-based nanoparticles, for instance, are widely utilized as pharmacological and biomedical imaging molecules, and hence offer a lot of potential for the development of versatile targeted therapy compositions. These nanoparticles have been used for cancer diagnosis and cancer treatments recently. We evaluate major innovations based on silver nanotheranostics technologies in this review paper, with an emphasis on cancer treatment implications. The present review covers papers, from 2010 to 2020.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"175-186"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9158831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Pyrrolidine derivatives as antibacterial agents, current status and future prospects: a patent review. 吡咯烷类衍生物抗菌现状及展望:专利综述。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-11-01 DOI: 10.4155/ppa-2022-0015
Aeyaz A Bhat, Nitin Tandon, Runjhun Tandon
{"title":"Pyrrolidine derivatives as antibacterial agents, current status and future prospects: a patent review.","authors":"Aeyaz A Bhat,&nbsp;Nitin Tandon,&nbsp;Runjhun Tandon","doi":"10.4155/ppa-2022-0015","DOIUrl":"https://doi.org/10.4155/ppa-2022-0015","url":null,"abstract":"<p><p>Bacterial infections are increasingly epitomizing major global health concerns, with rising death rates. Since the most complete assessment of the worldwide impact of antimicrobial resistance to date, with over 1.2 million people dead in 2019 as a direct result of antibiotic-resistant bacterial infections. The majority of antimicrobial drugs have been associated with a multitude of adverse effects including financial costs as well. Pyrrolidine derivatives have sparked the interest of researchers to create novel synthetic molecules with minimal side effect and drawbacks. To close the research gap, the current review discusses the synthetic compounds with active pyrrolidine scaffolds, critical findings and most crucially the structure-activity relationship that affects the activity of the ring over the last one and half decade.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 6","pages":"187-198"},"PeriodicalIF":1.3,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9158330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer. 高度稳定、无毒、功能化的纳米乳，用于癌症的早期诊断和改善。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-09-01 Epub Date: 2022-10-06 DOI: 10.4155/ppa-2021-0029
Ramesh Joga, Christy J Pulini-Kunnel, Chetan D Sabanis, Simran, Sandeep Kumar, Neeraj Kumar
{"title":"Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer.","authors":"Ramesh Joga,&nbsp;Christy J Pulini-Kunnel,&nbsp;Chetan D Sabanis,&nbsp;Simran,&nbsp;Sandeep Kumar,&nbsp;Neeraj Kumar","doi":"10.4155/ppa-2021-0029","DOIUrl":"https://doi.org/10.4155/ppa-2021-0029","url":null,"abstract":"<p><p><b>Aim:</b> To overcome the limitations associated with conventional formulations for cancer treatment by the effective utilization of nanoemulsion with therapy and diagnosis through the single unit. <b>Patent:</b> US20210275687 describes the usage of functionalized various oil-in-water nanoemulsions as pharmacological vehicles with theranostic potential in cancer treatment. <b>Materials & methods:</b> Vitamin E, oleic acid, sphingomyelin, ligands for functionalization, contrast agents and therapeutic biomolecules. <b>Results:</b> The toxicity studies conducted on healthy mice did not show any apparent toxicity issues. The stability studies conducted at 40 °C and 75% relative humidity, which is mandatory for regulatory approval, indicated the adequate physical stability of the formulation. <b>Conclusion:</b> The studies exhibited the promising theranostic potential of the developed nanoemulsion for the effective management and diagnosis of cancer and metastatic diseases.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 5","pages":"155-162"},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33490176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patent highlights February-March 2022. 专利亮点:2022年2月至3月。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-07-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0013
Hermann Am Mucke
{"title":"Patent highlights February-March 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0013","DOIUrl":"https://doi.org/10.4155/ppa-2022-0013","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 4","pages":"119-126"},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40634287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Six drugs facing key patent expirations and potential generic entry from May to June 2022. 2022年5月至6月，6种药物面临关键专利到期和潜在仿制药上市。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-07-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0018
Yali Friedman
{"title":"Six drugs facing key patent expirations and potential generic entry from May to June 2022.","authors":"Yali Friedman","doi":"10.4155/ppa-2022-0018","DOIUrl":"https://doi.org/10.4155/ppa-2022-0018","url":null,"abstract":"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"11 4","pages":"127-129"},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent update on drug patent linkage system in China. 中国药品专利联动制度最新进展。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2022-06-14 DOI: 10.4155/ppa-2022-0012
Weiwei Han
{"title":"Recent update on drug patent linkage system in China.","authors":"Weiwei Han","doi":"10.4155/ppa-2022-0012","DOIUrl":"https://doi.org/10.4155/ppa-2022-0012","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"1 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42932865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信